Skip to main navigation
  • About SIGA
  • Products
  • Investors
    • Press Releases
    • Events & Presentations
    • Financial Information
      • SEC Filings
    • Corporate Governance
      • Management
      • Board of Directors
      • Committee Composition
      • Contact the Board
      • Contact Audit Committee
    • Stock Information
    • Investor FAQs
    • Investor Contact
  • News
  • Careers
  • Contact

SIGA: Human BioArmor

Providing solutions for unmet needs in health security
  • About SIGA
  • Products
  • Investors
  • News
  • Careers
  • Contact

Press Release Details

Investors
  • Press Releases
  • Events & Presentations
  • Financial Information
    • SEC Filings
  • Corporate Governance
    • Management
    • Board of Directors
    • Committee Composition
    • Contact the Board
    • Contact Audit Committee
  • Stock Information
  • Investor FAQs
  • Investor Contact

Tove’ Bolken shares perspective on what biopharmaceutical companies can expect in manufacturing for 2021 and beyond

November 30, 2020 at 12:00 PM EST
Tove’ Bolken shares perspective on what biopharmaceutical companies can expect …

Latest Press Releases

Feb 26, 2021
SIGA Technologies to Host Business Update Call on March 4, 2021 Following Release of Year End 2020 Financial Results
Jan 13, 2021
SIGA Announces Public Health Agency of Canada Contract Award to Purchase Up To Approximately $33 Million of Oral TPOXX®
Nov 30, 2020
Tove’ Bolken shares perspective on what biopharmaceutical companies can expect in manufacturing for 2021 and beyond

Shareholder Tools

Print
Email Alerts
RSS News Feeds
Contact IR

SIGA: Human BioArmor

  • Corporate Headquarters
    31 East 62nd Street
    New York, NY 10065
    (212) 672-9100

  • SIGA Development Operations
    4575 SW Research Way, Suite 110
    Corvallis, OR 97333
    (541) 753-2000

  • Privacy Policy

© SIGA Technologies, All Rights Reserved